AstraZeneca PLC
- 取引所
- 米国株
- 国 / 地域
- USA
- 上場日
- 1993年5月17日
- 従業員数
- 96,100
- 公式サイト
- www.astrazeneca.com
総合バリュエーションレンジ · 保守的 $124–$132 / 妥当 $166–$224 / 楽観的 $242–$264。$169.64 時点で 妥当な本源的価値レンジ内。
レポート公開時 $178.75（2026年6月15日）
データ提供：EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
沿革
AstraZeneca traces its roots to two European pharmaceutical lines: Astra AB, founded in 1913 in Södertälje, Sweden, and Zeneca, spun off from ICI's pharmaceutical business in 1993. In 1999 Astra AB merged with the UK's Zeneca PLC to form AstraZeneca PLC (formerly Zeneca Group PLC; incorporated in 1992, headquartered in Cambridge, UK). After Pascal Soriot became CEO in October 2012, the company shifted toward oncology, CVRM, and biologics, deepened its Daiichi Sankyo ADC collaboration in 2019, and acquired Alexion for $39 billion in 2021 to enter rare disease. In February 2026 it moved its US listing to direct common shares on the NYSE, with the prior ADS delisted on 2026-01-30.
業界での地位
AstraZeneca is a biopharmaceutical company in the Drug Manufacturers - General industry, employing about 96,100 people and reporting 2025 revenue of $58.739 billion. It sells prescription medicines in over 125 countries across oncology, CVRM, respiratory and immunology, rare disease, and vaccines, with a deep late-stage pipeline of 21 late-stage NMEs and 186 projects as of Q1 2026. In Q1 2026 oncology accounted for 44% of revenue, CVRM 22%, respiratory and immunology 15%, and rare disease 16%. With a market capitalization of about $277.09 billion, it ranks among large pharmaceutical peers such as Novartis (~$299.5 billion), Merck (~$294 billion), Eli Lilly (over $1,015.1 billion), Bristol Myers Squibb (~$116.7 billion), and Pfizer (~$150.2 billion).